How does engineered C. butyricum cross the blood-brain barrier to directly bind GLP-1 receptors?
PARTIALLY ADDRESSED
The abstract claims C. butyricum-GLP-1 crosses the BBB and binds to GLP-1 receptors, but this is mechanistically implausible for a bacterial organism. The mechanism by which a gut bacterium could traverse the BBB and the actual source of GLP-1 receptor binding remains unexplained.
Gap type: unexplained_observation
Source paper: Engineered Clostridium butyricum-pMTL007-GLP-1 Delays Neurodegeneration in Prnp-SNCA*A53T Transgenic Mice Model by Suppressing Astrocyte Senescence. (2026, Probiotics and antimicrobial proteins, PMID:40627051)
Landscape Summary:
How does engineered C. butyricum cross the blood-brain barrier to directly bind GLP-1 receptors? is a 0.89 priority gap in neurodegeneration.
It has 0 linked hypotheses with average composite score 0.000.
Status: partially_addressed.
Key Unanswered Questions
What is the optimal TREM2 modulation strategy across disease stages?
How does DAM activation state affect therapeutic outcomes?
What biomarkers predict response to TREM2-targeted interventions?
Key Researchers
Colonna, Sevlever, et al. (TREM2 biology)
Clinical Trials
How does engineered C. butyricum cross the blood-brain barrier to directly bind GLP-1 receptors? — INVOKE-2 (completed)